Breaking News

Synthetic Genomics Launches cGMP Synthetic Biology Suite

Customized suite to support Phase I study of Advaxis’ personalized cancer immunotherapy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Synthetic Genomics, Inc. and Advaxis, Inc. have completed development and deployment of the first cGMP synthetic biology facility for the production of synthetic DNA constructs. The cGMP suite has been designed to meet Phase I clinical quality and manufacturing requirements mandated by the FDA. The suite will be used to develop synthetic DNA constructs for Advaxis’ upcoming Phase I trial of ADXS-NEO, a personalized, neoantigen-targeted cancer immunotherapy.   The suite is based on the BioXp 32...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters